North America Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

Description

List of Tables

The North America transdermal drug delivery system market is expected to grow from US$ 14,977.62 million in 2022 to US$ 20,958.37 million by 2030. It is estimated to register a CAGR of 4.3% from 2022 to 2030.

Increasing Prevalence of Chronic Diseases Drives North America Transdermal Drug Delivery System Market

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

According to the Alzheimer's association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer's dementia. The percentage of people with Alzheimer's dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer's dementia. According to the "Global Prevalence of Young-Onset Dementia" report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.

Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.

Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer's disease, and diabetes bolster the growth of the transdermal drug delivery system market.

North America Transdermal Drug Delivery System Market Overview

The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.

The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy's Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.

North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

North America Transdermal Drug Delivery System Market Segmentation

The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.

Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.

Product Code: TIPRE00013277

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Transdermal Drug Delivery System Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
- 4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
- 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
- 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - North America Market Analysis

5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
- 6.3.1 Overview
- 6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Drug-in-Adhesive Patches
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Matrix Patches
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.3 Reservoir Membrane Patches
    - 6.3.2.3.1 Overview
    - 6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.4 Vapor Patches
    - 6.3.2.4.1 Overview
    - 6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
- 6.4.1 Overview
- 6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
- 6.5.1 Overview
- 6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
- 7.4.1 Overview
- 7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
- 7.5.1 Overview
- 7.5.2 Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.1 Opioid
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.2 Non-Opioid
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
- 7.6.1 Overview
- 7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.2 Testosterone Replacement
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
- 7.7.1 Overview
- 7.7.2 Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

9.1 North America Transdermal Drug Delivery System Market
- 9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Johnson & Johnson
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Lavipharm SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Purdue Pharma LP
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 UCB SA
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms